Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy

Eftimov, Filip; Winer, John; Vermeulen, M.; Haan, Rob de; Schaik, Ivo N. van

doi:10.1002/14651858.cd001797.pub3

Cited by 148 publications

(174 citation statements)

References 57 publications

Supporting

Mentioning

157

Contrasting

Unclassified

Order By: Relevance

“…A Cochrane review recently summarized IVIG studies in CIDP, pointing to an improvement of disability, for at least 2-6 weeks, compared with placebo, and having a similar efficacy to PLEX, oral prednisolone, and intravenous methylprednisolone (see below) [50].…”

Section: Ivigmentioning

confidence: 99%

Immunotherapy in Peripheral Neuropathies

Léger¹,

Guimarães‐Costa²,

Muntean³

2016

Neurotherapeutics

View full text Add to dashboard Cite

Immunotherapy has been investigated in a small subset of peripheral neuropathies, including an acute one, Guillain-Barré syndrome, and 3 chronic forms: chronic inflammatory demyelinating polyradiculoneuropathy, multifocal motor neuropathy, and neuropathy associated with IgM anti-myelin-associated glycoprotein. Several experimental studies and clinical data are strongly suggestive of an immune-mediated pathogenesis. Either cell-mediated mechanisms or antibody responses to Schwann cell, compact myelin, or nodal antigens are considered to act together in an aberrant immune response to cause damage to peripheral nerves. Immunomodulatory treatments used in these neuropathies aim to act at various steps of this pathogenic process. However, there are many phenotypic variants and, consequently, there is a significant difference in the response to immunotherapy between these neuropathies, as well as a need to improve our knowledge and long-term management of chronic forms.

show abstract

Section: Ivigmentioning

confidence: 99%

Immunotherapy in Peripheral Neuropathies

Léger¹,

Guimarães‐Costa²,

Muntean³

2016

Neurotherapeutics

View full text Add to dashboard Cite

show abstract

“…9,10 In chronic inflammatory demyelinating polyneuropathy, evidence for the use of immunoglobulin (2 g/kg) is supported by a meta-analysis of seven RCTs involving 287 patients. 11 Compared with placebo, immunoglobulin resulted in significantly higher rates of improvement overall (44%, 95% confidence interval [CI] 32% to 62%, v. 18%) and reduction in degree of disability (relative risk [RR] 2.4, 95% CI 1.72 to 3.36) over study durations of two to six weeks. The short-term efficacy of intravenous immunoglobulin is similar to that of plasma exchange and corticosteroid therapy but with a better tolerance profile.…”

Section: Neurologic Disordersmentioning

confidence: 99%

Intravenous immunoglobulin as clinical immune-modulating therapy

Gilardin

Bayry

Kaveri

2015

CMAJ

View full text Add to dashboard Cite

“…Based on a Cochrane review, disability is reduced in 54% of CIDP patients within the first 6 weeks after IVIg therapy [Eftimov et al 2013]. Several trials and case series have demonstrated a response rate of even 60% during a short observation period over 24 weeks of IVIg treatment [Dyck et al 1982;Vermeulen et al 1993;Waniewski et al 1994;Hahn et al 1996b;Mendell et al 2001;Mehndiratta and Hughes, 2002;Hughes et al 2008b;Frauger et al 2011].…”

Section: Introductionmentioning

confidence: 99%

Two years’ long-term follow up in chronic inflammatory demyelinating polyradiculoneuropathy: efficacy of intravenous immunoglobulin treatment

Ellrichmann

Gold

Ayzenberg

et al. 2016

Ther Adv Neurol Disord

View full text Add to dashboard Cite

Background: Administration of intravenous immunoglobulins (IVIgs) is established for longterm treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Prevention of secondary axonal loss going along with permanent clinical disability and muscular atrophy is a major aim in CIDP therapy. To assess long-term clinical efficacy of IVIg treatment despite heterogenous disease course and variable complaints reported by the patients, long-term electrophysiological monitoring was performed for systematic evaluation of therapeutic efficacy of IVIg. Methods: A total of 21 patients with CIDP treated with IVIg 1 g/kg bodyweight every 3-6 weeks were examined electrophysiologically every 12 months over a period of 2 years. Results: Assessment of clinical symptoms, using the Inflammatory Neuropathy Cause and Treatment (INCAT) and Hughes functional grading score (F-score) revealed improvement of motor and sensory symptoms over a period of 2 years. As electrophysiological results remained stable, IVIg treatment seems to be suitable to prevent axonal loss in CIDP. Conclusions: This study confirms efficacy of IVIg as firstline therapy in CIDP. Doses and frequency of IVIg application should be adapted based on clinical evaluation and analysis of long-term electrophysiological findings.

show abstract

Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy

Cited by 148 publications

References 57 publications

Immunotherapy in Peripheral Neuropathies

Immunotherapy in Peripheral Neuropathies

Intravenous immunoglobulin as clinical immune-modulating therapy

Two years’ long-term follow up in chronic inflammatory demyelinating polyradiculoneuropathy: efficacy of intravenous immunoglobulin treatment

Contact Info

Product

Resources

About